The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.

dc.contributor.authorLewinska, Monika
dc.contributor.authorSantos-Laso, Alvaro
dc.contributor.authorArretxe, Enara
dc.contributor.authorAlonso, Cristina
dc.contributor.authorZhuravleva, Ekaterina
dc.contributor.authorJimenez-Agüero, Raul
dc.contributor.authorEizaguirre, Emma
dc.contributor.authorPareja, María Jesús
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorArrese, Marco
dc.contributor.authorSuppli, Malte P
dc.contributor.authorKnop, Filip K
dc.contributor.authorOversoe, Stine Karlsen
dc.contributor.authorVilladsen, Gerda Elisabeth
dc.contributor.authorDecaens, Thomas
dc.contributor.authorCarrilho, Flair Jose
dc.contributor.authorde Oliveira, Claudia Pms
dc.contributor.authorSangro, Bruno
dc.contributor.authorMacias, Rocio I R
dc.contributor.authorBanales, Jesus M
dc.contributor.authorAndersen, Jesper B
dc.date.accessioned2025-01-07T14:36:28Z
dc.date.available2025-01-07T14:36:28Z
dc.date.issued2021-10-29
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is affecting more people globally. Indeed, NAFLD is a spectrum of metabolic dysfunctions that can progress to hepatocellular carcinoma (NAFLD-HCC). This development can occur in a non-cirrhotic liver and thus, often lack clinical surveillance. The aim of this study was to develop non-invasive surveillance method for NAFLD-HCC. Using comprehensive ultra-high-performance liquid chromatography mass-spectrometry, we investigated 1,295 metabolites in serum from 249 patients. Area under the receiver operating characteristic curve was calculated for all detected metabolites and used to establish their diagnostic potential. Logistic regression analysis was used to establish the diagnostic score. We show that NAFLD-HCC is characterised by a complete rearrangement of the serum lipidome, which distinguishes NAFLD-HCC from non-cancerous individuals and other HCC patients. We used machine learning to build a diagnostic model for NAFLD-HCC. We quantified predictive metabolites and developed the NAFLD-HCC Diagnostic Score (NHDS), presenting superior diagnostic potential compared to alpha-fetoprotein (AFP). Patients' metabolic landscapes show a progressive depletion in unsaturated fatty acids and acylcarnitines during transformation. Upregulation of fatty acid transporters in NAFLD-HCC tumours contribute to fatty acid depletion in the serum. NAFLD-HCC patients can be efficiently distinguished by serum metabolic alterations from the healthy population and from HCC patients related to other aetiologies (alcohol and viral hepatitis). Our model can be used for non-invasive surveillance of individuals with metabolic syndrome(s), allowing for early detection of NAFLD-HCC. Therefore, serum metabolomics may provide valuable insight to monitor patients at risk, including morbidly obese, diabetics, and NAFLD patients. The funding sources for this study had no role in study design, data collection, data analyses, interpretation or writing of the report as it is presented herein.
dc.identifier.doi10.1016/j.ebiom.2021.103661
dc.identifier.essn2352-3964
dc.identifier.pmcPMC8577325
dc.identifier.pmid34740106
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8577325/pdf
dc.identifier.unpaywallURLhttp://www.thelancet.com/article/S2352396421004552/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26529
dc.journal.titleEBioMedicine
dc.journal.titleabbreviationEBioMedicine
dc.language.isoen
dc.organizationSAS - Hospital Universitario Juan Ramón Jiménez
dc.page.number103661
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHCC
dc.subjectNAFLD
dc.subjectbiomarker discovery
dc.subjectlipidomics
dc.subjectmetabolomics
dc.subject.meshBiomarkers
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshCase-Control Studies
dc.subject.meshGene Expression Profiling
dc.subject.meshHumans
dc.subject.meshLipidomics
dc.subject.meshLipids
dc.subject.meshLiver Neoplasms
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.meshPrognosis
dc.subject.meshROC Curve
dc.subject.meshReproducibility of Results
dc.subject.meshWorkflow
dc.titleThe altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number73

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8577325.pdf
Size:
3.46 MB
Format:
Adobe Portable Document Format